Investing.com - Morphosys AG reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Morphosys AG announced earnings per share of €-11.16 on revenue of €52.9M. Analysts polled by Investing.com anticipated EPS of €-4.12 on revenue of €44.01M.
Morphosys AG shares are down 28% from the beginning of the year and are trading at €23.940 , down-from-52-week-high.They are under-performing the STOXX 600 which is down 8.06% year to date.
Morphosys AG follows other major Healthcare sector earnings this month
Morphosys AG's report follows an earnings missed by Merck on Thursday, March 3, 2022, who reported EPS of €2.06 on revenue of €5.21B, compared to forecasts EPS of €2.12 on revenue of €5.17B.
Bayer had beat expectations on Tuesday, March 1, 2022 with first quarter EPS of €1.26 on revenue of €11.12B, compared to forecast for EPS of €0.9938 on revenue of €10.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar